Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Atlantia Clinical Trials: Investigating the interrelation of microbiology and immunology

Atlantia Clinical Trials investigates the role of microbiomes in immunity, focusing on gut and lung interactions to develop innovative health solutions.

From Atlantia Clinical Trials 28 Feb 2025

Study highlights increase in VZV-induced CNS infections and dementia risk

Researchers from Fujita Health University, Japan, observed a rise in adult central nervous system (CNS) infections, primarily aseptic meningitis caused by the varicella zoster virus (VZV), post-2019. The researchers highlighted the potential of zoster vaccination to reduce CNS infections.

27 Feb 2025

Nasal spray may offer new hope for traumatic brain injury patients

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

27 Feb 2025

LabGenius Therapeutics appoints three experts to its team of scientific advisors

Pioneering therapeutic antibody optimization, LabGenius Therapeutics utilizes advanced technologies to improve drug development and clinical translation.

From LabGenius 27 Feb 2025

New antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.

25 Feb 2025

Sleep disruption linked to inflammatory immune changes and health risks

New research reveals insight into the impact sleep quality has on a person's immune system, and how it could be linked to the development of diseases such as obesity, diabetes, and cardiovascular diseases.

24 Feb 2025

Development of lymphoma following CAR-T cell therapy

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

22 Feb 2025

New human antibody shows promise for Ebola virus treatment

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics.

21 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Early gut microbiota linked to food sensitivities in infants

A study led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences (IMS) recently showed that certain gut bacteria found in one-month-old infants are associated with food sensitivities and the development of food allergies, particularly to eggs, while other types of bacteria are not.

21 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Blood immune cells found to impact cancer survival

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering technique developed by researchers at UCL and the Francis Crick Institute.

20 Feb 2025

Sapio Sciences Expands Leadership Team to Drive Growth

The appointment of Mike Hampton and the launch of a Scientific Office position Sapio Sciences at the forefront of AI-driven lab informatics and drug discovery.

From Sapio Sciences 20 Feb 2025

Vitamin E supplementation may reduce food allergy development in newborns

New research found that supplementing maternal diet with α-tocopherol, a form of vitamin E, can reduce the development of food allergy and anaphylaxis in newborn mice.

19 Feb 2025

New mRNA technique targets disease cells while sparing healthy ones

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

19 Feb 2025

Researchers identify MLC1 as potential target in multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies.

18 Feb 2025

ImmuneLENS method provides new insights into cancer prognosis

18 Feb 2025

2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China

Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.

14 Feb 2025

Leinco Technologies awarded $1M grant to develop rapid test for intestinal immunity to polio

Leinco Technologies, a leader in antibody and protein development, is thrilled to announce that it has been awarded a $1 M grant from the Gates Foundation.

From Leinco Technologies 14 Feb 2025

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumor histology.

14 Feb 2025